Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Open access
Kaufman, Howard L., Kirkwood, John M., Hodi, F. Stephen, Agarwala, Sanjiv, Amatruda, Thomas, Bines, Steven D., Clark, Joseph I., Curti, Brendan, Ernstoff, Marc S., Gajewski, Thomas, Gonzalez, Rene, Hyde, Laura Jane, Lawson, David, Lotze, Michael, Lutzky, Jose, Margolin, Kim, McDermott, David F., Morton, Donald, Pavlick, Anna, Richards, Jon M., Sharfman, William, Sondak, Vernon K., Sosman, Jeffrey, Steel, Susan, Tarhini, Ahmad, Thompson, John A., Titze, Jill, Urba, Walter, White, Richard, Atkins, Michael B. · 2013 · Nature Reviews Clinical Oncology

Abstract

Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts--including physicians, nurses, and patient advocates--to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2013.153

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 196

Metadata

Authors
Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., Clark, J. I., Curti, B., Ernstoff, M. S., Gajewski, T., Gonzalez, R., Hyde, L. J., Lawson, D., Lotze, M., Lutzky, J., Margolin, K., McDermott, D. F., Morton, D., Pavlick, A., Richards, J. M., Sharfman, W., Sondak, V. K., Sosman, J., Steel, S., Tarhini, A., Thompson, J. A., Titze, J., Urba, W., White, R., & Atkins, M. B.
Venue
Nature Reviews Clinical Oncology
Published
2013-08-27
Volume
10
Issue
10
Pages
588-598
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W2018652183
Cited by
196
References
10
FWCI
3.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. https://app.cochat.ai/papers/10.1038/nrclinonc.2013.153
The paper
Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., Clark, J. I., Curti, B., Ernstoff, M. S., Gajewski, T., Gonzalez, R., Hyde, L. J., Lawson, D., Lotze, M., Lutzky, J., Margolin, K., McDermott, D. F., Morton, D., Pavlick, A., . . . Atkins, M. B. (2013). The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2013.153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.